GlassScriptPhysician profile
Eric T Tornga
NPI 1952908139
$8,642.77
in general payments reported to CMS, 2019-2025
41 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,604 · 2022: $1,928 · 2023: $2,102 · 2024: $1,993 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,110.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,390.13 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,363.35 | 2021-2025 | |
| Pfizer INC. | $895.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $775.38 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.02 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $721.18 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $272.59 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $266.31 | 2021-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $241.37 | 2021-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $196.62 | 2021-2023 | |
| Exact Sciences Corporation | $184.58 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $164.13 | 2021-2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $151.00 | 2021-2023 | Trintellix, Glassia |
| Merck Sharp & Dohme LLC | $128.34 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Kowa Pharmaceuticals America, INC. | $119.51 | 2021-2023 | Seglentis, Livalo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $104.27 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $93.18 | 2023 | Eliquis, Camzyos |
| Axsome Therapeutics, INC. | $92.38 | 2022-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $84.93 | 2024-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $68.82 | 2023-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $56.95 | 2021-2022 | |
| Dexcom, INC. | $47.90 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $44.37 | 2023-2024 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Currax Pharmaceuticals LLC | $42.16 | 2021-2023 | Contrave, Onzetra Xsail, Nexletol |
| Lexicon Pharmaceuticals, INC. | $41.63 | 2024 | |
| Sanofi Pasteur INC. | $39.99 | 2022-2023 | |
| Cranial Technologies, INC | $34.81 | 2024-2025 | Doc Band |
| Otsuka America Pharmaceutical, INC. | $33.69 | 2024-2025 | Rexulti |
| Philips North America LLC | $30.65 | 2021-2022 | |
| Lundbeck LLC | $23.30 | 2024 | Rexulti |
| Horizon Therapeutics Plc | $22.91 | 2022 | |
| Verona Pharma, INC. | $22.26 | 2025 | Ohtuvayre |
| Neurocrine Biosciences, INC. | $21.82 | 2024 | Ingrezza |
| Eisai INC. | $20.85 | 2021 | |
| Biogen, INC. | $19.16 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.55 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.05 | 2022 | |
| Hologic Sales and Service, LLC | $16.22 | 2024 | Aptima |
| Boston Scientific Corporation | $14.34 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.25 | 2025 | Qelbree |
| Esperion Therapeutics, INC. | $13.68 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tornga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.